-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s aggrastat active pharmaceutical ingredient has been approved.
Category:
Time：2022-09-07
Recently, the active pharmaceutical ingredient—aggrastat—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has been approved by the National Medical Products Administration for registration as an API intended for use in marketed formulations.
Recently, Agatoban, submitted by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Fourth Pharmaceutical Group, has been approved by the National Medical Products Administration for registration as an active pharmaceutical ingredient intended for use in marketed formulations.
It is understood that argatroban is a new-generation anticoagulant, belonging to the class of small-molecule direct thrombin inhibitors. Its formulations are primarily used in clinical treatment of peripheral arterial occlusive disease, as well as for the prevention or treatment of arterial thrombosis.
Focusing on a business development strategy centered on “active pharmaceutical ingredients (APIs) + finished dosage forms,” Shijiazhuang Fourth Pharmaceutical Group has vigorously implemented measures to extend, supplement, and strengthen its core industrial chains. Significant progress has been made in the R&D of specialty dosage forms and APIs. Since the beginning of this year, the group has obtained a total of 26 product approvals, including 16 finished dosage form varieties and 10 API varieties. Among these, four finished dosage form varieties have become the first-ever approved by domestic pharmaceutical companies.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license